One Chart to Understand｜Biocytogen 2025 Annual Results Announcement

About Biocytogen

Biocytogen (Stock Code: $Biocytogen(688796.CN); $BIOCYTOGEN-B(2315.HK)) is an international biotechnology company driven by innovative technology for new drug research and development, dedicated to becoming a global source of new drugs. With its self-developed gene editing technology at the core, the company has built a dual-engine platform of "Fully Human Antibody Library + Target Humanized Mouse Library" to systematically accelerate global drug development. Biocytogen has independently developed the RenMice^® fully human antibody platform (covering RenMab^®, RenLite^®, RenNano^®, RenTCR^®, RenTCR mimic™) for the discovery of therapeutic fully human monoclonal antibodies, bispecific/multispecific antibodies, bispecific ADCs, nanobodies, and TCR-like antibodies. Focusing on 1000+ potentially druggable targets, the company is advancing a large-scale antibody discovery program—"Thousand Mice, Ten Thousand Antibodies™"—and has constructed a library of over 1 million authentic fully human antibody sequences, opening up global collaboration. As of December 31, 2025, Biocytogen has signed over 350 drug co-development/licensing/transfer agreements. Its sub-brand, Biocytogen Animal, has established thousands of gene-edited animal/cell models, possesses a globally leading library of target humanized mice, and provides global clients with full-chain capability support including preclinical pharmacology and efficacy studies, gene editing services, and model construction. Biocytogen is headquartered in Beijing, with branches in China (Haimen, Jiangsu; Shanghai), the United States (Boston, San Francisco, San Diego), and Heidelberg, Germany, forming a global R&D and operational network.

$BIOCYTOGEN-B(02315.HK) $Biocytogen(688796.SH)